ChartMill assigns a Buy % Consensus number of 80% to GMDA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-01-29 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-12-05 | Needham | Reiterate | Buy -> Buy |
| 2023-11-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-15 | Needham | Reiterate | Buy -> Buy |
| 2023-06-30 | Needham | Reiterate | Buy -> Buy |
| 2023-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-19 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-05-16 | Needham | Reiterate | Buy -> Buy |
| 2023-05-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-04-20 | Needham | Maintains | Buy |
| 2023-04-19 | HC Wainwright & Co. | Maintains | Buy |
| 2023-04-18 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-28 | Oppenheimer | Maintains | Outperform |
| 2023-03-28 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-22 | Needham | Maintains | Buy |
| 2022-11-15 | Oppenheimer | Maintains | Outperform |
| 2022-09-29 | Needham | Maintains | Buy |
| 2021-11-16 | Needham | Maintains | Buy |
| 2021-11-16 | Oppenheimer | Maintains | Outperform |
| 2021-03-09 | Needham | Maintains | Buy |
10 analysts have analysed GMDA and the average price target is 4.42 USD. This implies a price increase of 13416.73% is expected in the next year compared to the current price of 0.0327.
The consensus rating for GAMIDA CELL LTD (GMDA) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering GAMIDA CELL LTD (GMDA) is 10.